Yahoo Finance

Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining other drugmakers that have promised to bolster domestic capabilities as they brace for tariffs from the Trump administration. Johnson & Johnson, Merck and Novartis are among the companies that have made investment pledges for the coming years, with an aggregate total of more than $200 billion. The administration is currently conducting an investigation into potential tariffs on the pharmaceutical industry.